Ford Motor Company vs Vir Biotechnology Inc. Common Stock — how do they compare? Ford Motor Company trades at $12.07 (market cap $48.25B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Ford Motor Company is far larger — about 26.8× Vir Biotechnology Inc. Common Stock's market cap, and Ford Motor Company pays a 4.96% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 105 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| F | VIR | |
|---|---|---|
Market Cap | $48.25B | $1.80B |
Volume | 33,627,673 | 1,782,836 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $11.78 |
52-Week Low | $11.21 | $5.12 |
Typical Hold Time | 105 Days | 0 Days |
Enterprise Value | $180.21B | $1.36B |
Dividend Yield | 4.96% | — |
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.05, up 0.42% on the day, with a mixed technical picture showing bearish moving averages but oversold RSI conditions. Fundamentally, the company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with negative profit margins and declining sales trends. Recent news highlights supplier disruptions affecting F-150 production and a 6.6% Q3 sales decline, though the company maintains its No. 3 U.S. market position.
Ford faces significant challenges with negative profitability and competitive pressures, though analyst consensus suggests 31% upside to the $15.79 price target. The stock presents a value opportunity given low P/S and P/B ratios, but investors must weigh operational headwinds against the company's strong commercial division and ongoing hybrid vehicle transition.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →